IFF Appoints J. Erik Fyrwald as Next CEO

International Flavors & Fragrances (IFF) has appointed J. Erik Fyrwald as next CEO and member of the company’s board of directors, effective Feb. 6, 2024. He will succeed Frank Clyburn, who will remain with the IFF until the end of March and will continue to work in an advisory capacity until December 2024.

Fyrwald brings to IFF more than four decades of executive and operational experience in the nutrition, agriculture and chemicals industries. He most recently served as CEO of Syngenta. Prior to that, he was CEO of Univar Solutions and Nalco, in addition to holding numerous global and regional executive leadership roles at DuPont, where he spent 27 years.

Fyrwald has been a member of Syngenta’s board of directors since 2004 and serves as an advisor to the chairman. He also serves on the boards of directors of Eli Lilly and the Swiss-American Chamber of Commerce.

Fyrwald received his bachelor’s degree from US University of Delaware in 1981 and participated in Harvard Business School’s Advanced Management Program in 1998.

Source: IFF
Source: IFF

Company

Logo:

International Flavors & Fragrances Inc. (IFF)

West 57th Street
NY 10019 New York
US

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.